



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)
)
Stevan D. Tofovic, et al.)
) Group Art Unit: 1614
Serial No.: 10/633,410)
) Examiner:
Filed: August 4, 2003)
)
For: AMINISTRATION OF ESTRADIOL)
)
METABOLITES FOR INHIBITION OF)
)
DRUG-INDUCED NEPHROTOXICITY)
)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


In compliance with the duty of disclosure as defined in 37 C.F.R. § 1.56 enclosed herewith for the Examiner's consideration is a copy of the publications listed on the attached Form PTO-1449. This statement is made pursuant to 37 C.F.R. § 1.97(b) since a first Office Action on the merits has not been mailed in the above-identified application.

This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that:

(1) additional information material to the examination of this application does not exist; (2) the information, protocols, results and the like reported by third parties are accurate or

enabling; or (3) the above information constitutes prior art to the subject invention.

Respectfully submitted,

By 
Mary-Elizabeth Buckles
Registration No. 31,907

REED SMITH LLP
Attorneys for Applicant

Mary-Elizabeth Buckles
1301 K Street, N.W.
Suite 1100-East Tower
Washington, D.C. 20005
(202) 414-9267

Filed: January 15, 2004


 (3)

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

EXAMINER: Initial citati n c nsid r d. Draw line thr ough citati n if n t in c nf rmance and n t considered. Include copy of this form with next communication to applicant.